5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
Public ClinicalTrials.gov record NCT01749956. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of 5-Fluorouracil (5-FU), Aflibercept, and Radiation for the Preoperative and Adjuvant Treatment of Patients With Stage II/III Rectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this Phase II study will be to investigate the antiangiogenic agent, aflibercept, in combination with chemoradiation as preoperative treatment for patients with stage II/III rectal cancer, followed by 4 months of FOLFOX6 plus aflibercept adjuvantly.
Study identification
- NCT ID
- NCT01749956
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 39 participants
Conditions and interventions
Conditions
Interventions
- Radiation Radiation
- Aflibercept Drug
- Surgery Procedure
- FOLFOX6 Drug
Radiation · Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2012
- Primary completion
- Aug 31, 2015
- Completion
- Aug 31, 2015
- Last update posted
- Feb 6, 2017
2013 – 2015
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Florida Cancer Specialists | Fort Myers | Florida | 33916 | — |
| Woodlands Medical Specialists | Pensacola | Florida | 32503 | — |
| Florida Cancer Specialists | St. Petersburg | Florida | 33705 | — |
| Space Coast Cancer Center | Titusville | Florida | 32796 | — |
| Baptist Hospital East | Louisville | Kentucky | 40207 | — |
| Oncology Hematology Care, Inc. | Cincinnati | Ohio | 45242 | — |
| Oklahoma University | Oklahoma City | Oklahoma | 71304 | — |
| South Carolina Oncology Associates | Columbia | South Carolina | 29210 | — |
| Tennessee Oncology - Chattanooga | Chattanooga | Tennessee | 37404 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01749956, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 6, 2017 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01749956 live on ClinicalTrials.gov.